WallStSmart

MEDIFAST INC (MED)vsService Corporation International (SCI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Service Corporation International generates 1017% more annual revenue ($4.31B vs $385.79M). SCI leads profitability with a 12.6% profit margin vs -4.8%. MED appears more attractively valued with a PEG of 0.97. SCI earns a higher WallStSmart Score of 62/100 (C+).

MED

Hold

45

out of 100

Grade: D

Growth: 2.0Profit: 2.0Value: 6.7Quality: 6.0
Piotroski: 2/9Altman Z: 5.46

SCI

Buy

62

out of 100

Grade: C+

Growth: 4.7Profit: 8.0Value: 8.0Quality: 3.3
Piotroski: 3/9Altman Z: 0.52
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for MED.

SCIOvervalued (-5.6%)

Margin of Safety

-5.6%

Fair Value

$79.95

Current Price

$78.79

$1.16 premium

UndervaluedFair: $79.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MED3 strengths · Avg: 9.3/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Altman Z-ScoreHealth
5.4610/10

Safe zone — low bankruptcy risk

PEG RatioValuation
0.978/10

Growing faster than its price suggests

SCI2 strengths · Avg: 9.0/10
Return on EquityProfitability
32.7%10/10

Every $100 of equity generates 33 in profit

Operating MarginProfitability
25.5%8/10

Strong operational efficiency at 25.5%

Areas to Watch

MED4 concerns · Avg: 2.5/10
Market CapQuality
$109.91M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-9.1%2/10

ROE of -9.1% — below average capital efficiency

Revenue GrowthGrowth
-36.9%2/10

Revenue declined 36.9%

SCI3 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.7%4/10

1.7% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Altman Z-ScoreHealth
0.522/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : MED

The strongest argument for MED centers on Price/Book, Altman Z-Score, PEG Ratio. PEG of 0.97 suggests the stock is reasonably priced for its growth.

Bull Case : SCI

The strongest argument for SCI centers on Return on Equity, Operating Margin. PEG of 1.48 suggests the stock is reasonably priced for its growth.

Bear Case : MED

The primary concerns for MED are Market Cap, Piotroski F-Score, Return on Equity.

Bear Case : SCI

The primary concerns for SCI are Revenue Growth, Piotroski F-Score, Altman Z-Score.

Key Dynamics to Monitor

MED profiles as a turnaround stock while SCI is a value play — different risk/reward profiles.

SCI carries more volatility with a beta of 1.00 — expect wider price swings.

SCI is growing revenue faster at 1.7% — sustainability is the question.

SCI generates stronger free cash flow (132M), providing more financial flexibility.

Bottom Line

SCI scores higher overall (62/100 vs 45/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

MEDIFAST INC

CONSUMER CYCLICAL · PERSONAL SERVICES · USA

Medifast, Inc. manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutrition products in the United States and Asia-Pacific. The company is headquartered in Baltimore, Maryland.

Visit Website →

Service Corporation International

CONSUMER CYCLICAL · PERSONAL SERVICES · USA

Service Corporation International offers death care products and services in the United States and Canada. The company is headquartered in Houston, Texas.

Want to dig deeper into these stocks?